Publications
5674 Results
- Journal / Conference
- Blood 126(23):25; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral;
- Year
- 2015
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0777
Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777
- Journal / Conference
- Blood 126(23):518; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral;
- Year
- 2015
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1106
Pre-transplant R-Bendamustine induces high rates of minimal residual disease in MCL patients: Updated results of SWOG S1106: US intergroup study of a randomized phase II trial of R-HCVAD vs. R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma
- Journal / Conference
- Blood 126(23):578; American Society of Hematology Annual Meeting (Dec 5-8, Orlando, FL), oral;
- Year
- 2015
- Research Committee(s)
- Lymphoma
Results of US intergroup trial of response-adapted chemotherapy based on PET for non-bulky stage I and II hodgkin lymphoma (HL) (CALGB/Alliance 50604) (http://www.bloodjournal.org/content/126/23/578)
- Journal / Conference
- Blood 126(23):3803; American Society of Hematology Annual Meeting (Dec 5-8, 2015, poster;
- Year
- 2015
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0919
Report of the relapsed/refractory cohort of SWOG S0919: phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)
- Journal / Conference
- American Society of Hematology Annual Meeting (Dec 5-8, Orlando, FL), poster;
- Year
- 2015
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0806
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large b-cell lymphoma (DLBCL): SWOG S0806
- Journal / Conference
- Blood 126(23):2569; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), poster;
- Year
- 2015
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106
Effect of minimal residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia (SWOG S0106)
- Journal / Conference
- Blood 126(23):2576; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), poster;
- Year
- 2015
- Research Committee(s)
- Leukemia and Molecular Epidemiology
- Study Number(s)
- S0106
Defining the genomic make up of acute myeloid leukemia in adolescents and young Adults (AYA) – report from COG AAML03P1, AAML531 and SWOG S0106
- Journal / Conference
- Blood 126(23):1308; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), poster;
- Year
- 2015
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E2902
Tipifarnib as maintenance therapy In acute myeloid leukemia (AML) improves survival in women with high risk disease. Results of the phase III intergroup trial E2902
- Journal / Conference
- Blood 126(23):217; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral presentation;
- Year
- 2015
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E2906
Phase III randomized trial of clofarabine as induction and post-remission therapy vs. standard daunorubicin & cytarabine induction and intermediate dose cytarabine post-remission therapy, followed by decitabine maintenance vs. observation in newly-diagnosed acute myeloid leukemia in older adults (Age>/=60 Years): A trial of the ECOG-ACRIN Cancer Research Group (E2906)
- Journal / Conference
- Blood 126(23):688; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral presentation;
- Year
- 2015
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106, S0112, SWOG-8600, SWOG-9031, SWOG-9333, SWOG-9500, S9918